Professor, Medicine, University of Washington School of Medicine
Oncology
Dr. Brenda M. Sandmaier, MD
|
|
Give Review
Brenda Sandmaier practices Oncology. Brenda Sandmaier is a published doctor as well. She has 99 publications published. The latest was: Anti-CD45 radioimmunotherapy without TBI before BMT facilitates persistent haploidentical donor engraftment in a murine model. She accepts Medicare payments and is registered with Medicare.gov.
Publications
- Anti-CD45 radioimmunotherapy without TBI before BMT facilitates persistent haploidentical donor enGraftment in a murine model.
- Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.
- Urinary Elafin and Kidney Injury in Hematopoietic Cell Transplant Recipients.
- Central Nervous System Relapse in Adults with Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation.
- Failure-free survival after initial systemic treatment of Chronic graft-versus host disease.
- Pre-transplant comorbidities predict severity of Acute graft-versus-host disease and subsequent mortality.
- Urinary cytokines after HCT: evidence for renal inflammation in the pathogenesis of proteinuria and kidney Disease.
- Allogeneic hematopoietic cell transplantation for indolent non-Hodgkin Lymphoma: indications and outcomes.
- CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in Acute myeloid leukemia.
- A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic Cell transplant recipients.
- Significance of minimal residual Disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.
- Costs of Second Allogeneic Hematopoietic Cell Transplantation.
- Non-relapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic Cell transplantation.
- Graft-versus-host disease and Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.
- Incidence, risk factors and outcomes of sclerosis in patients with Chronic graft-versus-host disease.
- Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic Cell transplantation: prognostic relevance of the initial CD3+ T Cell ...
- Allogeneic Hematopoietic Cell Transplantation Following Minimal Intensity Conditioning: Predicting Acute Graft-vs.-Host Disease and Graft-vs.-Tumor Effects.
- Population Pharmacokinetics and Dose Optimization of Mycophenolic Acid in HCT Recipients Receiving Oral Mycophenolate Mofetil.
- Failure-free survival after second-line systemic treatment of Chronic graft-versus-host disease.
- Allogeneic hematopoietic Cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy.
- Conditioning with α-emitter based radioimmunotherapy in canine allogeneic hematopoietic Cell transplantation.
- The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic Cell transplantation.
- A Limited Sampling Schedule to Estimate Mycophenolic Acid Area Under the Concentration-Time Curve in Hematopoietic Cell Transplantation Recipients.
- Nonmalignant late effects and compromised functional status in survivors of hematopoietic Cell transplantation.
- Durable donor enGraftment after radioimmunotherapy using alpha-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transp...
- Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic Cell transplantation for advanced hematologic malignancies.
- Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with Acute myeloid leukemia undergoing hematopoietic cell transplantation.
- Cytopenias after day 28 in allogeneic hematopoietic Cell transplantation: impact ofrecipient/donor factors, transplant conditions and myelotoxic drugs.
- Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic Cell transplantation.
- Immunomodulatory effects induced by cytotoxic T lymphocyte antigen 4 immunoglobulin with donor peripheral blood mononuclear Cell infusion in canine major histocompatib...
- Decreased serum albumin as a biomarker for severe Acute graft-vs.-host disease after reduced-intensity allogeneic hematopoietic cell transplantation.
- Outcome of Acute myeloid leukemia patients with monosomal karyotype who undergo hematopoietic cell transplantation.
- Nonmyeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high risk Acute lymphoblastic leukemia.
- Histology and Time to Progression Predict Survival for Lymphoma Recurring after Reduced-Intensity Conditioning and Allogeneic Hematopoietic Cell Transplantation.
- A Phase I/II Study of Chemotherapy Followed by Donor Lymphocyte Infusion plus Interleukin-2 for Relapsed Acute Leukemia after Allogeneic Hematopoietic Cell Transplanta...
- Who is fit for allogeneic transplantation?
- Reduced mortality after allogeneic hematopoietic-Cell transplantation.
- Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival is Determined by Karyotype and Comorbidities.
- Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic Anemia in patients over 40 years of age.
- Impact of recipient statin treatment on Graft-versus-host disease after allogeneic hematopoietic cell transplantation.
- Evaluation of posttransplant methotrexate to facilitate enGraftment in the canine major histocompatibility complex-haploidentical nonmyeloablative transplant model.
- Pilot study of a (213)bismuth-labeled anti-CD45 mAb as a novel nonmyeloablative conditioning for DLA-haploidentical littermate hematopoietic transplantation.
- Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with Acute myeloid leukemia.
- Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem Cell transplantation and immunologic recovery in patients with hemat...
- Donor statin treatment protects against severe Acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation.
- Optimizing reduced-intensity conditioning regimens for Myeloproliferative neoplasms.
- Plerixafor-moblized stem cells alone are capable of inducing early enGraftment across the MHC-haploidentical canine barrier.
- Allogeneic hematopoietic Cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients...
- Defining the intensity of conditioning regimens: working definitions.
- Reagents for astatination of biomolecules. 4. Comparison of maleimido-closo-decaborate(2-) and meta-[(211)At]astatobenzoate conjugates for labeling anti-CD45 antibodie...
- Delaying DLA-haploidentical hematopoietic Cell transplantation after total body irradiation.
- Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first alloGrafts.
- A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic Cell transplant patients.
- Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic Cell transplantation.
- What is the role for donor natural killer Cells after nonmyeloablative conditioning?
- Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative alloGrafting.
- Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211.
- Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic Cell transplantation following nonmyeloablative conditioning for ...
- Five-year follow-up of patients with advanced chronic lymphocytic Leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
- C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T Cells from renal Cell carcinoma patients.
- HLA-haploidentical bone marrow transplantation for hematologic Malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.
- Hematopoietic Cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloab...
- Reduced-intensity conditioning followed by allogeneic hematopoietic Cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disord...
- Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's Lymphoma.
- Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and Chronic lymphoc...
- Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with Acute myeloid leukemia in first remission: combined FHCRC and M...
- Comparable outcomes after nonmyeloablative hematopoietic Cell transplantation with unrelated and related donors.
- Relapse risk in patients with malignant Diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
- Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic Cell transplantation.
- Comorbidity and disease status based risk stratification of outcomes among patients with Acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic ce...
- Extended mycophenolate mofetil and shortened cyclosporine failed to reduce Graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloab...
- Hematopoietic cell transplantation in patients with myelodysplastic syndrome or Acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patie...
- Nonmyeloablative unrelated donor hematopoietic Cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.
- Hematopoietic Cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia.
- Reduced intensity conditioning for allogeneic hematopoietic Cell transplantation: current perspectives.
- Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning.
- Factors associated with outcomes in allogeneic hematopoietic Cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic Cell tran...
- Dog leukocyte antigen-haploidentical stem cell alloGrafts after anti-CD44 therapy and nonmyeloablative conditioning in a preclinical canine model.
- Failure of donor lymphocyte infusion to prevent Graft rejection in dogs given DLA-identical marrow after 1 Gy of total body irradiation.
- Improving the efficacy of reduced intensity allogeneic transplantation for Lymphoma using radioimmunotherapy.
- Reduced incidence of Acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen.
- Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear Cell transplantation after nonmyeloablative conditioning: the effect of po...
- Extending postGrafting cyclosporine decreases the risk of severe Graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation.
- Treatment for Acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors.
- Outcomes with Myeloid malignancies.
- Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic Cell transplantation.
- Durable enGraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model.
- Prolonged allogeneic marrow enGraftment following nonmyeloablative conditioning using 100 cGy total body irradiation and pentostatin before and pharmacological immunos...
- Current status of hematopoietic stem Cell transplantation after nonmyeloablative conditioning.
- Hematopoietic Cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.
- Targeted Cancer therapy using radiolabeled monoclonal antibodies.
- Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic Leukemia.
- HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid Leukemia.
- Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem Cell transplantation.
- Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
- Comparison of ARF after myeloablative and nonmyeloablative hematopoietic Cell transplantation.
- Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell Lymphoma.
- Allogeneic hematopoietic Cell transplantation for metastatic renal Cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological r...
Schools
University of Alberta Faculty of Medicine And Dentistry
Kaiser Permanente Med Center
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Drug Facts
| NPI NUMBER | 1003906967 | |
| NPPES Provider LastName | SANDMAIER | |
| NPPES Provider FirstName | BRENDA | |
| NPPES Provider ZIPCode | 981950001 | |
| NPPES Provider State | WA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 24.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1003906967 |
| Last Name Of The Provider | SANDMAIER |
| First Name Of The Provider | BRENDA |
| View All |
Similar Doctors
|
|
Dr. David G. Maloney, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Georgiana K. Ellis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary L. Disis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ben M. Chue, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. John M. Pagel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ryan D. Cassaday, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Diana F. Hausman, MD |
|
|
Dr. Cassian K. Yee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew R. Rezvani, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Henry O. Otero, MD |
|
|
Dr. Candice McCoy, MD |